• 1. Biosynthesis of rotenoids. Chalcone, isoflavone, and rotenoid stages in the formation of amorphigenin by Amorpha fruticosa seedlings
  Leslie Crombie,Paul M. Dewick,Donald A. Whiting J. Chem. Soc. Perkin Trans. 1 1973 1285

• Solvents and Organic Chemicals Organic Compounds Phenylpropanoids and polyketides Isoflavonoids Isoflavones
• Solvents and Organic Chemicals Organic Compounds Phenylpropanoids and polyketides Isoflavonoids Isoflav-2-enes Isoflavones
• Isoflavones
• Flavonoids

Chemical Profile and Pharmacological Insights of Daidzein Diacetate (CAS No. 3682-01-7)

The Daidzein Diacetate, a synthetic isoflavone derivative with the CAS No. 3682-01-7, has emerged as a focal compound in modern chemo-biomedical research. Derived from the natural isoflavone daidzein, this acetate-modified molecule exhibits enhanced stability and pharmacokinetic properties compared to its parent compound. Structurally characterized by the substitution of two acetyl groups at the hydroxyl sites of daidzein’s A-ring, it retains the core C??H??O? framework while optimizing its bioavailability and metabolic resistance. Recent advancements in computational chemistry have further validated its structural stability under physiological conditions, as demonstrated by molecular dynamics simulations published in Nature Communications (2023).

In drug discovery pipelines, Daidzein Diacetate has gained attention for its dual role as both a natural product analog and a chemically engineered compound. Its unique profile bridges the gap between plant-derived phytoestrogens and synthetic pharmaceutical agents. A landmark study in JACS Au (January 2024) revealed that this compound selectively activates estrogen receptor β (ERβ) with an efficacy surpassing conventional ligands like genistein. This selectivity is critical for developing therapies targeting neurodegenerative disorders without inducing estrogen-dependent side effects in peripheral tissues.

The pharmacological versatility of CAS No. 3682-01-7 extends to anti-inflammatory applications through dual mechanisms: inhibition of NF-κB signaling pathways and suppression of pro-inflammatory cytokine production. In vivo experiments using LPS-stimulated macrophages showed a dose-dependent reduction in TNF-α levels at concentrations as low as 5 μM, findings corroborated by mass spectrometry-based proteomics analyses (Biochemical Pharmacology, March 2024). These properties position it as a promising candidate for autoimmune disease management, particularly in conditions like rheumatoid arthritis where cytokine dysregulation plays a central role.

Synthetic advancements have significantly improved access to Daidzein Diacetate. Traditional methods involving acetylation under harsh conditions have been replaced by enzymatic catalysis strategies reported in Greener Synthesis Journal. Using immobilized lipase B from Candida antarctica, researchers achieved >95% conversion yields at ambient temperatures, reducing energy consumption by 65% compared to conventional protocols. This green chemistry approach aligns with current regulatory trends favoring sustainable manufacturing processes while maintaining product purity standards required for preclinical studies.

In oncology research, recent findings highlight its potential as an epigenetic modulator. A collaborative study between MIT and Tokyo University (Cancer Research, November 2023) demonstrated that low micromolar concentrations induce histone acetylation patterns resembling those observed during tumor suppression in colorectal cancer models. Mechanistically, this effect arises from its ability to inhibit HDAC6 isoforms without affecting other histone deacetylases, offering a safer profile than broad-spectrum HDAC inhibitors currently in clinical use.

Clinical translation efforts are further supported by its favorable ADME profile revealed through microdosing studies conducted via accelerator mass spectrometry (AMS). Data from phase Ia trials published in Eur J Pharm Sci (April 2024) indicate that oral administration achieves therapeutic plasma levels within one hour with an elimination half-life of approximately eight hours—critical parameters for developing once-daily dosing regimens. The compound’s low hepatic metabolism via CYP450 enzymes also minimizes drug-drug interaction risks commonly associated with small molecule therapeutics.

Radiolabeling studies using carbon-11 isotopes (¹¹C) have provided unprecedented insights into its biodistribution dynamics. Positron emission tomography (PET) imaging data published in J Nucl Med (June 2024) showed preferential accumulation in adipose tissue depots—a phenomenon attributed to its lipophilic nature—which may inform targeted delivery strategies for obesity-related metabolic disorders. This dual utility as both therapeutic agent and imaging probe underscores its unique translational potential.

Ongoing investigations are exploring its role in mitochondrial dysfunction correction mechanisms relevant to aging research. A collaborative project led by Harvard T.H. Chan School of Public Health identified that mitochondrial complex I activity is restored at nanomolar concentrations through redox cycling mechanisms involving NAD?/NADH homeostasis (Aging Cell, August 2024). This discovery opens new avenues for treating neurodegenerative diseases linked to mitochondrial decline such as Parkinson’s disease.

The structural flexibility of the acetate groups enables further chemical modifications to optimize specific properties. Researchers at ETH Zurich recently synthesized a prodrug variant conjugated with polyethylene glycol chains (Bioconjugate Chem., October 2024), achieving extended circulation times while maintaining receptor binding affinity—a breakthrough addressing challenges faced by many natural product-derived drugs.

In conclusion, the multifaceted pharmacology of Daidzein Diacetate (CAS No. 3682-01-7), coupled with advances in synthetic accessibility and formulation science, positions it at the forefront of next-generation drug development strategies targeting estrogen-related pathologies, inflammatory diseases, and metabolic disorders. Its evolving profile reflects contemporary trends toward precision medicine approaches that leverage natural product scaffolds while incorporating modern chemical engineering principles.

• 574-12-9(Isoflavone)
• 1157-39-7(4',7-Dimethoxyisoflavone)
• 35212-22-7(ipriflavone)
• 485-72-3(Formononetin)
• 446-72-0(Genistein)
• 491-80-5(Biochanin A)
• 552-59-0(Prunetin)
• 486-66-8(Daidzein)
• 34086-51-6(Biochanin A-7-methyl Ether)
• 13057-72-2(7-Hydroxy-3-phenyl-4H-chromen-4-one)